Astellas and Sony ink deal to develop ADC platform

Using Sony Corporation’s KIRAVIA Backbone material, Astellas has partnered with the firm to jointly discover an ADC platform.

Millie Nelson, Editor

May 17, 2023

1 Min Read
Astellas and Sony ink deal to develop ADC platform
DepositPhotos/garagestock

Using Sony Corporation’s KIRAVIA Backbone material, Astellas Pharma has partnered with the firm to jointly discover an antibody-drug conjugate (ADC) platform.

The collaborative research agreement, of which financial details have not been disclosed, will focus on developing an ADC platform in oncology using Sony’s polymeric material, KIRAVIA Backbone, as a linker. The linker  delivers anti-cancer drugs to targeted cells and aims to improve therapeutic efficacy by reaching high Drug-to-Antibody Ratio (DAR).

According to both parties, the linkers conjugates antibodies and drugs and is pivotal to the development of a better-performing ADC.

Depositphotos_127561452_XL-300x200.jpg

DepositPhotos/garagestock

In addition, Japanese biopharma firm Astellas will run non-clinical trials of development candidates. Moreover, in an effort to build a drug discovery platform not limited to just ADCs as a modality, the pair will discuss expanding the research partnerships  to reach different targets.

“We are pleased to enter into a joint research agreement with Sony,” said Yoshitsugu Shitaka, chief scientific officer, Astellas.

“Astellas is working to create innovative drugs from a multifaceted perspective called the Focus Area approach, which identifies combinations of biology, therapeutic modality or technology and diseases with high unmet medical needs. The partnership will further strengthen our ability to utilize suitable modalities. It is our expectation that the collaboration will lead to the continuous creation of innovative drugs for patients around the world.”

In June 2022, Astellas partnered with Californian biotech Sutro Biopharma to codevelop immunostimulatory antibody-drug conjugates (iADCs) for three biological targets in a $90 million deal.

About the Author

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

You May Also Like